Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/4686/118/)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Grants PMA for QView Medical’s Automated Breast Ultrasound System
The device is meant for breast screening in asymptomatic dense breasted women whose mammograms returned negative.
Sandoz Announces Voluntary Recall of Potentially Contaminated Losartan
The affected product was distributed after October 8, according to the FDA.
